Verition Fund Management
GPCR icon

Verition Fund Management’s Structure Therapeutics GPCR Stock Holding History

Verition Fund Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,700
Closed -$201K – 3095
2024
Q1 		$201K Buy
+4,700
New +$198K ﹤0.01% 2500

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Verition Fund Management's GPCR Position: Q2 2026 in Review

Verition Fund Management increased its Structure Therapeutics (GPCR) stake by 1.6% in Q2 2026, buying an estimated $19.7K and bringing the position to 28,519 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #1231.

Verition Fund Management first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.44M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Verition Fund Management held 28,519 shares of Structure Therapeutics worth $1.53M as of Q2 2026.
  • Verition Fund Management bought 445 Structure Therapeutics shares in Q2 2026, an estimated $19.7K.
  • Structure Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1231 holding.
  • Verition Fund Management first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Verition Fund Management's Structure Therapeutics position peaked at $5.44M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.